News

CytoCore notes a market report projecting 41 percent annual growth in the area of molecular diagnostics and screening in the United States alone, with a market potential of $92 billion projected by 2016.

Argos Therapeutics initiates a Phase 1/2 clinical trial to test the immunologic activity and safety of its AGS-004 in HIV-infected adults.

LabVantage's Sapphire LIMS to serve as the core infrastructure for research and clinical labs of an academic medical center.

A set of molecular biomarkers might better predict the recurrence of bladder cancer than conventional prognostic features.

Researchers at the Dana-Farber Cancer Institute identify which malignant blood cells are highly vulnerable to a type of experimental drug that triggers apoptosis.

Abbott’s molecular Dx will remain untouched as GE will acquire two of Abbott’s diagnostics businesses for $8.13 billion in cash.

PMC believes that all genetic information, including family history, deserves strong and enforceable protections against misuse in health insurance and employment.

Warnex’s Medical Laboratories division will develop pharmacogenetic assays and serve as a central laboratory for several clinical studies of Schering-Plough Canada.

Dr Aslam will be responsible for all ongoing development programmes within Enigma, with emphasis on Enigma’s rapid diagnostics systems.

The agreement recognizes Illumina’s technology and development expertise with Mayo Clinic’s utility to establish new diagnostic technologies.